Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer - A combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG

Gynecologic Oncology

Volumn 129, Issue 3, 2013, Pages 463-466

  Heitz, Florian ^a   Du Bois, Andreas ^a   Harter, Philipp ^a   Lubbe, Dirk ^b   Kurzeder, Christian ^a   Vergote, Ignace ^c   Plante, Marie ^d   Pfisterer, Jacobus ^e  

^a KLINIKEN ESSEN MITTE   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d LAVAL UNIVERSITY   (Canada)

^e Gynecologic Oncology Center Kiel   (Germany)

Author keywords

Beta blocker; Platinum sensitive ovarian carcinoma; Response; Survival

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARBOPLATIN; GEMCITABINE; METOPROLOL; NEBIVOLOL; PROPRANOLOL; SOTALOL; TALINOLOL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MONITORING; DRUG SENSITIVITY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENT CANCER; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; YOUNG ADULT;

EID: 84877579246     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.03.007     Document Type: Article

References (23)

1. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 26 Dec 29 2011 2484 2496
2. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N. Engl. J. Med. 365 26 Dec 29 2011 2473 2483
3. P. Harter, Z.M. Muallem, C. Buhrmann, D. Lorenz, C. Kaub, and R. Hils Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer Gynecol. Oncol. 121 3 Jun 1 2011 615 619
4. C. Aghajanian, N. Finkler, T. Rutherford, D. Smith, H. Yi, and M. Parmar OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) J. Clin. Oncol. 30 17 Jun 10 2012 2039 2045 10.1200/JCO.2012.42.0505
5. E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, and G. Kristensen AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J. Clin. Oncol. 30 2012 (Suppl.; abstr LBA5002).
6. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 6 Mar 15 2009 1234 1244
7. D. Palm, K. Lang, B. Niggemann, TL Drell 4th, K. Mazur, and K.S. Zaenker The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers Int. J. Cancer 118 11 Jun 1 2006 2744 2749
8. K. Masur, B. Niggemann, K.S. Zanker, and F. Entschladen Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers Cancer Res. 61 7 Apr 1 2001 2866 2869
9. M. Benish, I. Bartal, Y. Goldfarb, B. Levi, R. Avraham, and A. Raz Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis Ann. Surg. Oncol. 15 7 Jul 2008 2042 2052
10. S.K. Lutgendorf, S. Cole, E. Costanzo, S. Bradley, J. Coffin, and S. Jabbari Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines Clin. Cancer Res. 9 12 Oct 1 2003 4514 4521
11. A.K. Sood, R. Bhatty, A.A. Kamat, C.N. Landen, L. Han, and P.H. Thaker Stress hormone-mediated invasion of ovarian cancer cells Clin. Cancer Res. 12 2 Jan 15 2006 369 375
12. J.W. Lee, M.M. Shahzad, Y.G. Lin, G. Armaiz-Pena, L.S. Mangala, and H.D. Han Surgical stress promotes tumor growth in ovarian carcinoma Clin. Cancer Res. 15 8 Apr 15 2009 2695 2702
13. A. Melhem-Bertrandt, M. Chavez-Macgregor, X. Lei, E.N. Brown, R.T. Lee, and F. Meric-Bernstam Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer J. Clin. Oncol. 29 19 Jul 1 2011 2645 2652
14. T.I. Barron, R.M. Connolly, L. Sharp, K. Bennett, and K. Visvanathan Beta blockers and breast cancer mortality: a population-based study J. Clin. Oncol. 29 19 Jul 1 2011 2635 2644
15. S. Lemeshow, H.T. Sorensen, G. Phillips, E.V. Yang, S. Antonsen, and A.H. Riis Beta-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study Cancer Epidemiol. Biomarkers Prev. 20 10 Oct 2011 2273 2279
16. D.G. Powe, M.J. Voss, K.S. Zanker, H.O. Habashy, A.R. Green, and I.O. Ellis Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival Oncotarget 1 7 Nov 2010 628 638
17. E.S. Diaz, B.Y. Karlan, and A.J. Li Impact of beta blockers on epithelial ovarian cancer survival Gynecol. Oncol. 127 2 Nov 2012 375 378
18. A. du Bois, H.J. Luck, J. Pfisterer, W. Schroeder, J.U. Blohmer, and R. Kimmig Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group Ann. Oncol. 12 8 Aug 2001 1115 1120
19. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, and A.J. Lacave Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J. Clin. Oncol. 24 29 Oct 10 2006 4699 4707
20. R Development CoreTeam R: a language and environment for statistical computing 2012 R Foundation for Statistical Computing Vienna, Austria Available from: http://www.R-project.org/.
21. P.H. Thaker, L.Y. Han, A.A. Kamat, J.M. Arevalo, R. Takahashi, and C. Lu Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat. Med. 12 8 Aug 2006 939 944
22. H. Itamochi, J. Kigawa, H. Sultana, T. Iba, R. Akeshima, and S. Kamazawa Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary Jpn. J. Cancer Res. 93 6 Jun 2002 723 728
23. R. Eskander, L. Randall, and L. Bessonova Beta blocker use and ovarian cancer survival: a retrospective cohort study Gynecol. Oncol. 125 #264 2012 S3 S167 [abstract]